REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet Age-Related Macular Degeneration (AMD)
Portfolio Pulse from Benzinga Newsdesk
REGENXBIO Inc. (NASDAQ:RGNX) announced the publication of Phase I/IIa trial results for ABBV-RGX-314, a gene therapy for wet AMD, in The Lancet. The study, showing positive results for safety and tolerability, supports ongoing pivotal trials of this potential one-time treatment.
March 28, 2024 | 11:09 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
REGENXBIO Inc. announced positive Phase I/IIa trial results for ABBV-RGX-314, a gene therapy for wet AMD, published in The Lancet, supporting ongoing pivotal trials.
The publication of positive trial results in a prestigious journal like The Lancet is a significant milestone for REGENXBIO. It not only validates the safety and tolerability of ABBV-RGX-314 but also supports the continuation of pivotal trials. This development is likely to be viewed positively by investors, potentially leading to an increase in stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90